- Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
- Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
- Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
- Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
- Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
- Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
- Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
More ▼
Key statistics
On Thursday, Aprea Therapeutics Inc (APRE:NAQ) closed at 5.59, 101.08% above the 52 week low of 2.78 set on Jul 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.80 |
---|---|
High | 5.90 |
Low | 5.33 |
Bid | 4.06 |
Offer | 6.50 |
Previous close | 5.59 |
Average volume | 10.60k |
---|---|
Shares outstanding | 5.43m |
Free float | 4.44m |
P/E (TTM) | -- |
Market cap | 30.35m USD |
EPS (TTM) | -3.32 USD |
Data delayed at least 15 minutes, as of May 16 2024 19:34 BST.
More ▼